Blood News and Research

RSS

ESC welcomes 'intriguing' study on heart failure

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.

31 Jan 2012

Study pinpoints genetic factors behind increased ALL risk in Hispanic children

Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease. Work led by St. Jude Children's Research Hospital scientists has pinpointed genetic factors behind the grim statistics.

31 Jan 2012

Ariz. hospitals fighting losses in political shift and in court; Ga. seeking second cancer center

A look at hospital news around the country also includes reports on a Mayo collaboration in Minnesota on immigrant health, plans for a proton cancer therapy center in South Florida and efforts by Tufts Medical Center to get a level one trauma center.

31 Jan 2012

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

31 Jan 2012

Engineers discover electrical property in arteries

The heart's inner workings are mysterious, perhaps even more so with a new finding. Engineers at the University of Washington have discovered an electrical property in arteries not seen before in mammalian tissues.

31 Jan 2012

Tailored approach may help prevent heavy drinking in college students

The first few weeks of college are a critical time in shaping students' drinking habits. Now Penn State researchers have a tailored approach that may help prevent students from becoming heavy drinkers.

31 Jan 2012

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

31 Jan 2012

MT2 gene mutations may increase risk of diabetes

Researchers in Lille and Paris demonstrated that mutations in the melatonin receptor gene (melatonin or the "hormone of darkness" induces sleep) lead to an almost sevenfold increase in the risk of developing diabetes.

31 Jan 2012

Cedars-Sinai Heart Institute to mark National Go Red for Women Day

Hundreds of health care professionals at the Cedars-Sinai Heart Institute will wear red on Friday, Feb. 3, to mark National Go Red for Women Day. The group will meet at 9 a.m. for a group photo to demonstrate support for increased research on heart disease, the No. 1 killer in the U.S. For the first time the annual gathering this year will include blood pressure checks and heart disease risk assessments.

31 Jan 2012

VPH's stroke center receives S. Mark Taper Foundation grant

The S. Mark Taper Foundation awarded a grant of $30,000 to Valley Presbyterian Hospital (VPH) for its Stroke Center, a state-of-the-art facility using the latest in telemedicine and diagnostic tools to ensure the best possible outcomes for its patients, Gustavo Valdespino, President and CEO of VPH, announced today.

31 Jan 2012

Idaho Technology submits FilmArray Respiratory Panel for FDA 510(k) clearance

Technology, Inc. announced today that it has filed a submission with the U.S. Food and Drug Administration for 510(k) clearance of five additional respiratory pathogens for its FilmArray Respiratory Panel, a user-friendly Multiplex PCR assay currently FDA cleared for 15 respiratory pathogens.

30 Jan 2012

For stroke prevention, large medical centers may have the edge

Despite advances in the diagnosis and treatment of unruptured brain aneurysms, outcomes have remained stagnant over the last 10 years. This can be explained by the dramatic proliferation of minimally invasive endoscopic coiling procedures at lower-volume community hospitals, where outcomes are inferior.

30 Jan 2012

Fewer getting screened for common cancers: CDC report

According to federal health officials last Thursday, the number of Americans being screened for colon, breast and cervical cancers still fall below national targets.

30 Jan 2012

In Florida, GOP presidential hopefuls wrestle with health policy issues

The candidates appear to be proceeding with caution regarding politically risky plans to overhaul Medicare while painting opponents in a harsh light.

30 Jan 2012

Research advances understanding of hypoxic response

A new family of proteins which regulate the human body's 'hypoxic response' to low levels of oxygen has been discovered by scientists at Barts Cancer Institute at Queen Mary, University of London and The University of Nottingham.

30 Jan 2012

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

From Baxter International Inc. 30 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Covidien Solitaire FR Revascularization Device approved for investigational use

Covidien, a leading global provider of healthcare products, today announced that the Solitaire™ FR Revascularization Device has been approved for investigational use in the Interventional Management of Stroke (IMS III) trial.

30 Jan 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

Researcher have identified thirty one regions of genome associated with circulating metabolites

In a study to the genetic variance of human metabolism, researchers have identified thirty one regions of the genome that were associated with levels of circulating metabolites, i.e., small molecules that take part in various chemical reactions of human body.

30 Jan 2012